Abiopharma

🔍 Hoang Thierry (Executive)

Company: SENSIENT TECHNOLOGIES CORP (SXT)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Sold 439 shares of Common Stock at $114.1514 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 14,309.00 | transaction_form_type: 4
• Holds 1,925 shares of Performance Stock Unit (Derivative)
  Date: 2026-05-04 | Code: H | shares_owned_after: 1,925.00 | Footnotes: F1, F2, F2
• Holds 1,610 shares of Performance Stock Unit (Derivative)
  Date: 2026-05-04 | Code: H | shares_owned_after: 1,610.00 | Footnotes: F1, F3, F3
• Holds 1,429 shares of Performance Stock Unit (Derivative)
  Date: 2026-05-04 | Code: H | shares_owned_after: 1,429.00 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each performance stock unit represents a contingent right to receive one share of Issuer's Common Stock.
• F2: Represents grant of performance stock units under Issuer's 2017 Stock Plan, as amended and restated. The award is eligible to vest following a three-year performance period (from January 1, 2024 through December 31, 2026) as follows: (1) 70% of the award is eligible to vest upon achievement of certain performance criteria based on EBITDA growth, and (2) 30% of the award is eligible to vest upon achievement of certain performance criteria based on return on invested capital. Subject to certain continued employment conditions and subject to accelerated vesting in certain circumstances, the actual number of shares earned will be determined and vest following the three-year performance period. The number of shares reflected is at the target award amount. No performance stock units will vest below a minimum level of performance. At or above the minimum level of performance, the actual number of shares earned may range from 0% to 200% of the target award amount.
• F3: Represents grant of performance stock units under Issuer's 2017 Stock Plan, as amended and restated. The award is eligible to vest following a three-year performance period (from January 1, 2025 through December 31, 2027) as follows: (1) 70% of the award is eligible to vest upon achievement of certain performance criteria based on EBITDA growth, and (2) 30% of the award is eligible to vest upon achievement of certain performance criteria based on return on invested capital. Subject to certain continued employment conditions and subject to accelerated vesting in certain circumstances, the actual number of shares earned will be determined and vest following the three-year performance period. The number of shares reflected is at the target award amount. No performance stock units will vest below a minimum level of performance. At or above the minimum level of performance, the actual number of shares earned may range from 0% to 200% of the target award amount.
• F4: The award is eligible to vest following a three-year performance period (from January 1, 2026 through December 31, 2028) based on applicable performance criteria related to revenue and return on invested capital and other terms and conditions. The number of shares reflected is at the target award amount, but the actual number of shares earned will depend on performance and may be more or less than such amount.